SCHEMBL14680701

SCHEMBL14680701

COC(=O)C12CC3CC(C1)C(NC(=O)C(C)(C)NC(=O)OC(C)(C)C)C(C3)C2

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 19/20 0.51
HSD11B2 P80365 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19529446 1.00 HSD11B1 (0.51) HSD11B1HSD11B2
SCHEMBL14680489 0.89 HSD11B1 (0.56) HSD11B1HSD11B2
SCHEMBL14680490 0.88 HSD11B1 (0.55) HSD11B1HSD11B2
SCHEMBL19529479 0.84 HSD11B1 (0.48) HSD11B1HSD11B2
SCHEMBL16945741 0.83 HSD11B1 (0.48) HSD11B1HSD11B2
SCHEMBL6338618 0.81 EPHX2 (0.51) HSD11B1
SCHEMBL16666346 0.80 HSD11B1 (0.50) HSD11B1HSD11B2
SCHEMBL232118 0.80 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL16666656 0.80 HSD11B1 (0.52) HSD11B1HSD11B2
Hydrochloric Acid SCHEMBL16666654 0.79 HSD11B1 (0.51) HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865664-B1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT BAMICHEM CO LTD (KR) 2017-11-01 EP disclosed
EP-2865664-B1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT BAMICHEM CO LTD (KR) 2017-11-01 EP disclosed
US-9464044-B2 Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) 2016-10-11 US disclosed
US-9464044-B2 Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) 2016-10-11 US disclosed
US-20150210635-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2015-07-30 US disclosed
US-20150210635-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2015-07-30 US disclosed
US-9073830-B2 Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same HYUNDAI PHARM CO., LTD. (KR) 2015-07-07 US disclosed
EP-2865664-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT BAMICHEM CO., LTD (KR) 2015-04-29 EP disclosed
EP-2865664-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT BAMICHEM CO., LTD (KR) 2015-04-29 EP disclosed
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2014-07-24 US disclosed
WO-2013019091-A2 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885
US-20150210635-A1 NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.